Historical Valuation
AnaptysBio Inc (ANAB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.54 is considered Undervalued compared with the five-year average of -3.98. The fair price of AnaptysBio Inc (ANAB) is between 10961.65 to 11166.12 according to relative valuation methord. Compared to the current price of 43.80 USD , AnaptysBio Inc is Undervalued By 99.6%.
Relative Value
Fair Zone
10961.65-11166.12
Current Price：43.80
99.6%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
AnaptysBio Inc (ANAB) has a current Price-to-Book (P/B) ratio of -42.14. Compared to its 3-year average P/B ratio of 11.39 , the current P/B ratio is approximately -469.98% higher. Relative to its 5-year average P/B ratio of 7.64, the current P/B ratio is about -651.72% higher. AnaptysBio Inc (ANAB) has a Forward Free Cash Flow (FCF) yield of approximately -11.68%. Compared to its 3-year average FCF yield of -17.43%, the current FCF yield is approximately -33.02% lower. Relative to its 5-year average FCF yield of -12.39% , the current FCF yield is about -5.77% lower.
P/B
Median3y
11.39
Median5y
7.64
FCF Yield
Median3y
-17.43
Median5y
-12.39
Competitors Valuation Multiple
AI Analysis for ANAB
The average P/S ratio for ANAB competitors is 9274.34, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB.O) exhibits a P/S ratio of 8.54, which is -99.91% above the industry average. Given its robust revenue growth of 154.26%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ANAB
1Y
3Y
5Y
Market capitalization of ANAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ANAB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ANAB currently overvalued or undervalued?
AnaptysBio Inc (ANAB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.54 is considered Undervalued compared with the five-year average of -3.98. The fair price of AnaptysBio Inc (ANAB) is between 10961.65 to 11166.12 according to relative valuation methord. Compared to the current price of 43.80 USD , AnaptysBio Inc is Undervalued By 99.60% .
What is AnaptysBio Inc (ANAB) fair value?
ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AnaptysBio Inc (ANAB) is between 10961.65 to 11166.12 according to relative valuation methord.
How does ANAB's valuation metrics compare to the industry average?
The average P/S ratio for ANAB's competitors is 9274.34, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB) exhibits a P/S ratio of 8.54, which is -99.91% above the industry average. Given its robust revenue growth of 154.26%, this premium appears sustainable.
What is the current P/B ratio for AnaptysBio Inc (ANAB) as of Jan 09 2026?
As of Jan 09 2026, AnaptysBio Inc (ANAB) has a P/B ratio of -42.14. This indicates that the market values ANAB at -42.14 times its book value.
What is the current FCF Yield for AnaptysBio Inc (ANAB) as of Jan 09 2026?
As of Jan 09 2026, AnaptysBio Inc (ANAB) has a FCF Yield of -11.68%. This means that for every dollar of AnaptysBio Inc’s market capitalization, the company generates -11.68 cents in free cash flow.
What is the current Forward P/E ratio for AnaptysBio Inc (ANAB) as of Jan 09 2026?
As of Jan 09 2026, AnaptysBio Inc (ANAB) has a Forward P/E ratio of -20.48. This means the market is willing to pay $-20.48 for every dollar of AnaptysBio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for AnaptysBio Inc (ANAB) as of Jan 09 2026?
As of Jan 09 2026, AnaptysBio Inc (ANAB) has a Forward P/S ratio of 8.54. This means the market is valuing ANAB at $8.54 for every dollar of expected revenue over the next 12 months.